Loading organizations...
§ Private Profile · Nutley, NJ, USA
Hoffman-LaRoche, Roche Institute of Molecular Biology is a company.
Key people at Hoffman-LaRoche, Roche Institute of Molecular Biology.
The Roche Institute of Molecular Biology was a significant basic science research center focused on molecular biology and biochemistry. Operating as an independent entity within Hoffmann-La Roche, the institute concentrated on fundamental biological discovery, translating its findings into potential biomedical advancements. Its research led to key developments such as Abuscreen, a drug abuse detection product, and Aferon, a recombinant alpha-interferon.
The institute was established on July 14, 1967, following the initiative of John Burns, then Vice President of Research at Hoffman-La Roche. Burns successfully recruited biochemist Sidney Udenfriend from the National Institutes of Health to direct the new facility in Nutley, New Jersey. The foundational insight was to foster unconstrained basic scientific inquiry within an industrial environment, marrying academic freedom with corporate resources.
The primary beneficiaries of the institute's work included the global scientific community, through its extensive publications, and the pharmaceutical industry, through its contributions to drug discovery and diagnostics. The long-term vision was to push the boundaries of molecular biological understanding, thereby laying groundwork for new therapeutic and diagnostic modalities that would ultimately improve human health.
Key people at Hoffman-LaRoche, Roche Institute of Molecular Biology.
Hoffmann‑La Roche (commonly “Roche”) is a global, research‑based healthcare company; the Roche Institute of Molecular Biology (RIMB) was an independent basic‑research laboratory established and funded by Roche in Nutley, New Jersey (late 1960s–1990s). Below is a focused profile that treats Roche as the parent firm and RIMB as its notable research‑center portfolio entity.
High‑Level Overview
For an investment‑style summary (applied to Roche as a corporate investor of research):
For RIMB as a portfolio research entity:
Origin Story
Core Differentiators
Role in the Broader Tech / Life‑Sciences Landscape
Quick Take & Future Outlook
Key sources